Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis

Pediatric Pulmonology

Volumn 48, Issue 9, 2013, Pages 874-884

  Winterstein, Almut G ^a,b   Eworuke, Efe ^a   Xu, Dandan ^a   Schuler, Pamela ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

cohort study; Medicaid; national cystic fibrosis patient registry; respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; CYSTIC FIBROSIS; DEATH; DISEASE REGISTRY; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOPROPHYLAXIS; INFANT; MAJOR CLINICAL STUDY; MALE; PHARMACY; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT INFECTION; RISK FACTOR; SEASON;

COHORT STUDY; MEDICAID; NATIONAL CYSTIC FIBROSIS PATIENT REGISTRY; RESPIRATORY SYNCYTIAL VIRUS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; COHORT STUDIES; CYSTIC FIBROSIS; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; REGISTRIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 84882453075     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22711     Document Type: Article

References (26)

1. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ,. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA-J Am Med Assoc 1999; 282: 1440-1446.
2. Medicine NLo. Synagis (palivizumab) injection, solution [MedImmune, LLC]. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8e35c4c8-bf56-458f-a73c- 8f5733829788. Accessed July 2, 2012.
3. Hampp C, Kauf TL, Saidi AS, Winterstein AG,. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med 2011; 165: 498-505.
4. Prescott WA, Doloresco F, Brown J, Paladino JA,. Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review. Pharmacoeconomics 2010; 28: 279-293.
5. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-537.
6. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, Connor EM, Sondheimer HM;, Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143: 532-540.
7. Committee on Infectious Disease. From the American Academy of Pediatrics: policy statements-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124: 1694-1701.
8. Wat D, Doull I,. Respiratory virus infections in cystic fibrosis. Paediatr Respir Rev 2003; 4: 172-177.
9. Hiatt PW, Grace SC, Kozinetz CA, Raboudi SH, Treece DG, Taber LH, Piedra PA,. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 1999; 103: 619-626.
10. Armstrong D, Grimwood K, Carlin JB, Carzino R, Hull J, Olinsky A, Phelan PD,. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol 1998; 26: 371-379.
11. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ,. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 1988; 113: 826-830.
12. Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G,. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J 2012; 31: 5-9.
13. Iwane MK, Edwards KM, Szilagyi PG, Walker FJ, Griffin MR, Weinberg GA, Coulen C, Poehling KA, Shone LP, Balter S, Hall CB, Erdman DD, Wooten K, Schwartz B;, New Vaccine Surveillance Network. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 2004; 113: 1758-1764.
14. Malfroot A, Adam G, Ciofu O, Döring G, Knoop C, Lang AB, Van Damme P, Dab I, Bush A;, European Cystic Fibrosis Society (ECFS) Vaccination Group. Immunisation in the current management of cystic fibrosis patients. J Cyst Fibros 2005; 4: 77-87.
15. Cystic Fibrosis Foundation, Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Spear SL, Michel SH, Parad RB, White TB, Farrell PM, Marshall BC, Accurso FJ,. Cystic fibrosis foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 2009; 155: S73-S93.
16. Saldanha I, McKoy NA, Robinson KA,. Palivizumab for prophylaxis against respiratory syncytial virus (RSV) infection in children with cystic fibrosis: results of a Cochrane systematic review. Pediatr Pulmonol 2010; S33: 331.
17. Cohen A, Boron M, Dingivan C,. A phase IV study of the safety of Synagis (palivizumab) for prophylaxis of respiratory syncytial virus disease in children with cystic fibrosis [abstract]. American Thoracic Society International Conference 2005. p. A178.
18. Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S,. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol 2008; 43: 169-174.
19. McCormick J, Southern KW,. A survey of palivizumab for infants with cystic fibrosis in the UK. Arch Dis Child 2007; 92: 87-88.
20. Speer ME, Fernandes CJ, Boron M, Groothuis JR,. Use of palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis. Pediatr Infect Dis J 2008; 27: 559-561.
21. Chow CW, Landau LI, Taussig LM,. Bronchial mucous glands in the newborn with cystic fibrosis. Eur J Pediatr 1982; 139: 240-243.
22. van Ewijk BE, van der Zalm MM, Wolfs TF, Fleer A, Kimpen JL, Wilbrink B, van der Ent CK,. Prevalence and impact of respiratory viral infections in young children with cystic fibrosis: prospective cohort study. Pediatrics 2008; 122: 1171-1176.
23. van Ewijk BE, van der Zalm MM, Wolfs TF, van der Ent CK,. Viral respiratory infections in cystic fibrosis. J Cyst Fibros 2005; 4: 31-36.
24. Miller AL, Bowlin TL, Lukacs NW,. Respiratory syncytial virus-induced chemokine production: linking viral replication to chemokine production in vitro and in vivo. J Infect Dis 2004; 189: 1419-1430.
25. Van Ewijk BE, Wolfs TF, Aerts PC, Van Kessel KP, Fleer A, Kimpen JL, Van der Ent CK,. RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr Res 2007; 61: 398-403.
26. Winterstein AG, Hampp C, Saidi A,. Effectiveness of palivizumab prophylaxis in infants and children in Florida. Pharmacoepidemiol Drug Saf 2012; 21: 53-60.